Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director G. Walmsley Graham sold 700,761 shares of the business's stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total transaction of $4,730,136.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Olema Pharmaceuticals Stock Down 4.7 %
OLMA opened at $6.14 on Wednesday. The company has a market cap of $351.81 million, a P/E ratio of -2.80 and a beta of 1.92. The firm's 50-day moving average price is $10.50 and its 200-day moving average price is $11.85. Olema Pharmaceuticals, Inc. has a 52-week low of $6.08 and a 52-week high of $16.77.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $27.00.
Check Out Our Latest Stock Analysis on OLMA
Institutional Trading of Olema Pharmaceuticals
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Biden broke it... Now Trump is going to fix it.
Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry.
Several large investors have recently bought and sold shares of OLMA. Victory Capital Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 9.9% during the third quarter. Victory Capital Management Inc. now owns 851,512 shares of the company's stock worth $10,167,000 after buying an additional 76,720 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock worth $3,949,000 after acquiring an additional 207,565 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Olema Pharmaceuticals during the 2nd quarter worth about $945,000. Point72 Asset Management L.P. purchased a new stake in Olema Pharmaceuticals during the 2nd quarter valued at about $34,753,000. Finally, Dana Investment Advisors Inc. acquired a new position in shares of Olema Pharmaceuticals in the second quarter valued at about $808,000. Hedge funds and other institutional investors own 91.78% of the company's stock.
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
